BMS
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
CHMP Issues Positive Opinion for BMS's Breyanzi in Third-Line Follicular Lymphoma
The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.
Opdivo, Yervoy Outperform Single-Agent Immunotherapy in First-Line MSI-High, dMMR Colorectal Cancer
Premium
Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.
JP Morgan Healthcare Conference, Day 1: Vertex, Bristol Myers Squibb, Gilead, Sarepta, and More
On the first day, Vertex discussed regulatory plans for a kidney disease drug, BMS and Merck talked about pipeline diversification, and Gilead offered updates on anito-cel.
Immunocore Outlines Strategic Priorities on Kimmtrak and TCR Therapy Pipeline
The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.